Compare Ginkgo Bioworks Holdings Inc (DNA) vs Lamb Weston Holdings Inc (LW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Lamb Weston Holdings Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M), while Lamb Weston Holdings Inc trades at $52.4 (market cap $7.23B). The key difference: Lamb Weston Holdings Inc is far larger — about 14.3× Ginkgo Bioworks Holdings Inc's market cap, and Lamb Weston Holdings Inc pays a 2.89% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.
| DNA | LW | |
|---|---|---|
Market Cap | $505.73M | $7.23B |
Sector | Health | Consumer Staples |
52-Week High | $16.14 | $66.57 |
52-Week Low | $5.48 | $38.48 |
Enterprise Value | $607.68M | $11.10B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
Lamb Weston (LW) trades at $51.81, down 0.88% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 16.28% ROE and a 4.39% net margin, supported by positive cash flow from operations of $868.3M in 2025. Recent news highlights Q4 2026 results exceeding expectations and a declared $0.38 dividend.
Outlook remains positive with a consensus price target of $53.86, though risks include margin pressure from cost inflation and international headwinds. The stock offers a solid dividend yield and growth potential from operational improvements, but investors should monitor debt levels and competitive dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Lamb Weston Holdings Inc
Lamb Weston is the world's second-largest producer of branded and private-label frozen potato products, such as French fries, sweet potato fries, tater tots, diced potatoes, mashed potatoes, hash browns, and chips. The company also has a small appetizer business that produces onion rings, mozzarella sticks, and cheese curds. Including joint ventures, 63% of fiscal 2022 revenue was U.S.-based, with the remainder stemming from Europe, Canada, Japan, China, Korea, Mexico, and several other countries. Lamb Weston's customer mix is estimated 58% quick-serve restaurants, 19% full-service restaurants, 8% other food services (hotels, commercial cafeterias, arenas, schools), and 16% retail. Lamb Weston became an independent company in 2016 when it was spun off from Conagra.
Read more on LW →
